

Table S1. The list of primers used in this study.

| | Forward sequence (5'-3') | Reverse sequence (5'-3') | Amplicon | No. of Molecular probe |
|--------------|----------------------------|--------------------------|----------|------------------------|
| ABCB1 | AGCCCTTGGAATTATTTCTTTTATTA | ATGTATCGGAGCCGCTTG | 93 bp | 78# |
| ABCB4 | AACCTCTGATTGACAGCTACAGTG | GGGTGGGATAGTTGAACACG | 96 bp | 41# |
| ABCG2 | GCAACAGGAAACAATCCTTGTA | AAGGCCACGTGATTCTTCC | 110 bp | 45# |
| ABCC2 | TGCTGGGAGAAAATGGAAAAT | CAGGACTGCTGTGGGACATA | 76 bp | 9# |
| GAPDH | TCCACTGGCGTCTTCACC | GGCAGAGATGATGACCCTTTT | 78 bp | 45# |

Table S2. The concentration of drugs, dilution range and serial dilution factors used in present study.

| | Stock (mg mL ⁻¹) | Dilutions range (µg mL ⁻¹) | | | | | Serial Dilution factor |
|--------------|------------------------------|--|------------|------------|--------------|------------|------------------------|
| | | A2780 | A2780 CDDP | SK-OV-3 | SK-OV-3 CDDP | MRC-5 pd19 | |
| 1 | 25 | 10–0.156 | 10–0.156 | 100–1.56 | 100–1.56 | 100–1.56 | 2x |
| 1+5FU | 25 | 10–0.156 | 10–0.156 | 100–1.56 | 100–1.56 | 100–1.56 | 2x |
| 1+GEM | 25 | 10–0.156 | 10–0.156 | 100–1.56 | 100–1.56 | 100–1.56 | 2x |
| 2 | 25 | 100–1.56 | 100–1.56 | 300–4.68 | 400–6.25 | 400–6.25 | 2x |
| 3 | 20 | 100–1.56 | 100–1.56 | 300–4.68 | 300–4.68 | 300–4.68 | 2x |
| 4 | 20 | 100–1.56 | 100–1.56 | 300–4.68 | 400–6.25 | 400–6.25 | 2x |
| 5 | 25 | 100–1.56 | 100–1.56 | 300–4.68 | 400–6.25 | 400–6.25 | 2x |
| 6 | 25 | 100–1.56 | 100–1.56 | 300–4.68 | 400–6.25 | 400–6.25 | 2x |
| 7 | 25 | 100–1.56 | 100–1.56 | 300–4.68 | 400–6.25 | 400–6.25 | 2x |
| CDDP | 1 | 15–0.23 | 15–0.23 | 15–0.23 | 15–0.23 | 30–0.47 | 2x |
| 5FU | 50 | 100–0.0001 | 100–0.0001 | 200–0.0002 | 200–0.0002 | 200–0.0002 | 10x |
| GEM | 100 | 100–0.0001 | 100–0.0001 | 100–0.0001 | 100–0.0001 | 10000–0.01 | 10x |